Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies

por Wei, Spencer C., Anang, Nana-Ama A. S., Sharma, Roshan, Andrews, Miles C., Reuben, Alexandre, Levine, Jacob H., Cogdill, Alexandria P., Mancuso, James J., Wargo, Jennifer A., Pe’er, Dana, Allison, James P.
Publicado 2019

Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC

por Saddawi-Konefka, Robert, O’Farrell, Aoife, Faraji, Farhoud, Clubb, Lauren, Allevato, Michael M., Jensen, Shawn M., Yung, Bryan S., Wang, Zhiyong, Wu, Victoria H., Anang, Nana-Ama, Msari, Riyam Al, Schokrpur, Shiruyeh, Pietryga, Ida Franiak, Molinolo, Alfredo A., Mesirov, Jill P., Simon, Aaron B., Fox, Bernard A., Bui, Jack D., Sharabi, Andrew, Cohen, Ezra E. W., Califano, Joseph A., Gutkind, J. Silvio
Publicado 2022